Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants

Nirsevimab to Prevent RSV Illness in InfantsNirsevimab, a monoclonal antibody targeting respiratory syncytial virus, protected against RSV-associated hospitalization and severe lower respiratory tract infection in term and late-preterm infants.

Automated summary

Nirsevimab, a monoclonal antibody, effectively prevents hospitalization and severe lower respiratory tract infection in term and late-preterm infants caused by respiratory syncytial virus (RSV).